CN1313767A - 氨基甲酸酯和脲组合物以及神经营养用途 - Google Patents
氨基甲酸酯和脲组合物以及神经营养用途 Download PDFInfo
- Publication number
- CN1313767A CN1313767A CN99810011A CN99810011A CN1313767A CN 1313767 A CN1313767 A CN 1313767A CN 99810011 A CN99810011 A CN 99810011A CN 99810011 A CN99810011 A CN 99810011A CN 1313767 A CN1313767 A CN 1313767A
- Authority
- CN
- China
- Prior art keywords
- straight
- branched alkyl
- alkyl
- branched alkenyl
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title description 26
- 239000000203 mixture Substances 0.000 title description 22
- 239000004202 carbamide Substances 0.000 title description 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 title description 12
- 230000000508 neurotrophic effect Effects 0.000 title description 9
- -1 small molecule carbamates Chemical class 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 230000001537 neural effect Effects 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 134
- 125000003342 alkenyl group Chemical group 0.000 claims description 82
- 150000001875 compounds Chemical class 0.000 claims description 79
- 125000000304 alkynyl group Chemical group 0.000 claims description 52
- 239000001257 hydrogen Substances 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 49
- 150000002431 hydrogen Chemical class 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 40
- 210000002569 neuron Anatomy 0.000 claims description 29
- 229910052760 oxygen Inorganic materials 0.000 claims description 27
- 239000003018 immunosuppressive agent Substances 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- 150000002148 esters Chemical class 0.000 claims description 20
- 230000007850 degeneration Effects 0.000 claims description 19
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 19
- 230000001861 immunosuppressant effect Effects 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 210000005036 nerve Anatomy 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 12
- 150000003254 radicals Chemical class 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
- 230000002093 peripheral effect Effects 0.000 claims description 10
- 230000008929 regeneration Effects 0.000 claims description 10
- 238000011069 regeneration method Methods 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000005493 quinolyl group Chemical group 0.000 claims description 9
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 8
- 208000029028 brain injury Diseases 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 230000002969 morbid Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 210000000278 spinal cord Anatomy 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 230000000626 neurodegenerative effect Effects 0.000 claims description 7
- 230000000638 stimulation Effects 0.000 claims description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 6
- 125000005002 aryl methyl group Chemical group 0.000 claims description 6
- 125000005605 benzo group Chemical group 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 150000003053 piperidines Chemical class 0.000 claims description 6
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical compound C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 claims description 6
- RRBYUSWBLVXTQN-VZCHMASFSA-N tricyclene Natural products C([C@@H]12)C3C[C@H]1C2(C)C3(C)C RRBYUSWBLVXTQN-VZCHMASFSA-N 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- ZBLQOJLMBDJYLD-GKAPJAKFSA-N (2S)-1-(2-methylbutylcarbamoyl)pyrrolidine-2-carboxylic acid Chemical compound CCC(C)CNC(=O)N1CCC[C@H]1C(O)=O ZBLQOJLMBDJYLD-GKAPJAKFSA-N 0.000 claims description 3
- PFTHAXRKSYEYLR-JTQLQIEISA-N (2S)-1-(cyclohexylcarbamothioyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=S)NC1CCCCC1 PFTHAXRKSYEYLR-JTQLQIEISA-N 0.000 claims description 3
- MCMRHIIVSHWBEA-JTQLQIEISA-N (2s)-1-(cyclohexylcarbamoyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)NC1CCCCC1 MCMRHIIVSHWBEA-JTQLQIEISA-N 0.000 claims description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims description 3
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 3
- LORRLQMLLQLPSJ-UHFFFAOYSA-N 1,3,5-trithiane Chemical compound C1SCSCS1 LORRLQMLLQLPSJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 3
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 3
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical compound CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 claims description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 3
- FICAQKBMCKEFDI-UHFFFAOYSA-N 3,5-dimethyl-1,2-oxazole Chemical compound CC=1C=C(C)ON=1 FICAQKBMCKEFDI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 3
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 3
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims description 3
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 3
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims description 3
- 125000005936 piperidyl group Chemical group 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 102000000521 Immunophilins Human genes 0.000 abstract description 17
- 108010016648 Immunophilins Proteins 0.000 abstract description 17
- 235000013877 carbamide Nutrition 0.000 abstract 1
- 150000003672 ureas Chemical class 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000002585 base Substances 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 101710103508 FK506-binding protein Proteins 0.000 description 7
- 101710104425 FK506-binding protein 2 Proteins 0.000 description 7
- 101710104423 FK506-binding protein 3 Proteins 0.000 description 7
- 101710104333 FK506-binding protein 4 Proteins 0.000 description 7
- 101710104342 FK506-binding protein 5 Proteins 0.000 description 7
- 101710149710 FKBP-type 16 kDa peptidyl-prolyl cis-trans isomerase Proteins 0.000 description 7
- 101710121306 FKBP-type 22 kDa peptidyl-prolyl cis-trans isomerase Proteins 0.000 description 7
- 101710180800 FKBP-type peptidyl-prolyl cis-trans isomerase FkpA Proteins 0.000 description 7
- 101710104030 Long-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 description 7
- 101710114693 Outer membrane protein MIP Proteins 0.000 description 7
- 101710116692 Peptidyl-prolyl cis-trans isomerase Proteins 0.000 description 7
- 101710111764 Peptidyl-prolyl cis-trans isomerase FKBP10 Proteins 0.000 description 7
- 101710111749 Peptidyl-prolyl cis-trans isomerase FKBP11 Proteins 0.000 description 7
- 101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 description 7
- 101710111757 Peptidyl-prolyl cis-trans isomerase FKBP14 Proteins 0.000 description 7
- 101710111682 Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 description 7
- 101710111689 Peptidyl-prolyl cis-trans isomerase FKBP1B Proteins 0.000 description 7
- 101710147154 Peptidyl-prolyl cis-trans isomerase FKBP2 Proteins 0.000 description 7
- 101710147149 Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 description 7
- 101710147152 Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 description 7
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 description 7
- 101710147150 Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 description 7
- 101710147138 Peptidyl-prolyl cis-trans isomerase FKBP7 Proteins 0.000 description 7
- 101710147137 Peptidyl-prolyl cis-trans isomerase FKBP8 Proteins 0.000 description 7
- 101710147136 Peptidyl-prolyl cis-trans isomerase FKBP9 Proteins 0.000 description 7
- 101710174853 Peptidyl-prolyl cis-trans isomerase Mip Proteins 0.000 description 7
- 101710200991 Peptidyl-prolyl cis-trans isomerase, rhodopsin-specific isozyme Proteins 0.000 description 7
- 101710092145 Peptidyl-prolyl cis-trans isomerase-like 1 Proteins 0.000 description 7
- 101710092146 Peptidyl-prolyl cis-trans isomerase-like 2 Proteins 0.000 description 7
- 101710092148 Peptidyl-prolyl cis-trans isomerase-like 3 Proteins 0.000 description 7
- 101710092149 Peptidyl-prolyl cis-trans isomerase-like 4 Proteins 0.000 description 7
- 101710113444 Probable parvulin-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 description 7
- 101710090737 Probable peptidyl-prolyl cis-trans isomerase Proteins 0.000 description 7
- 101710133309 Putative peptidyl-prolyl cis-trans isomerase Proteins 0.000 description 7
- 101710124237 Short-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 description 7
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 7
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- 229930182821 L-proline Natural products 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 229940124589 immunosuppressive drug Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000002241 neurite Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 208000035126 Facies Diseases 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 210000005064 dopaminergic neuron Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 description 2
- 241001598984 Bromius obscurus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000003858 Chymases Human genes 0.000 description 2
- 108090000227 Chymases Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007697 cis-trans-isomerization reaction Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- MHJJUOJOAJLYBS-ZBRNBAAYSA-N (2s)-2-aminopropanoic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound C[C@H](N)C(O)=O.OC(=O)[C@@H]1CCCN1 MHJJUOJOAJLYBS-ZBRNBAAYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- PFTHAXRKSYEYLR-UHFFFAOYSA-N 1-(cyclohexylcarbamothioyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=S)NC1CCCCC1 PFTHAXRKSYEYLR-UHFFFAOYSA-N 0.000 description 1
- MCMRHIIVSHWBEA-UHFFFAOYSA-N 1-(cyclohexylcarbamoyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)NC1CCCCC1 MCMRHIIVSHWBEA-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N 1-propanol Substances CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VJROPLWGFCORRM-UHFFFAOYSA-N 2-methylbutan-1-amine Chemical compound CCC(C)CN VJROPLWGFCORRM-UHFFFAOYSA-N 0.000 description 1
- GELMWIVBBPAMIO-UHFFFAOYSA-N 2-methylbutan-2-amine Chemical compound CCC(C)(C)N GELMWIVBBPAMIO-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- ZBLQOJLMBDJYLD-UHFFFAOYSA-N CCC(C)CNC(=O)N1CCCC1C(O)=O Chemical compound CCC(C)CNC(=O)N1CCCC1C(O)=O ZBLQOJLMBDJYLD-UHFFFAOYSA-N 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010072220 Cyclophilin A Proteins 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WBOHXLDSPBIPTP-UHFFFAOYSA-N N,N-dimethyl-1,8-naphthyridin-4-amine Chemical compound CN(C1=CC=NC2=NC=CC=C12)C WBOHXLDSPBIPTP-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 102100034539 Peptidyl-prolyl cis-trans isomerase A Human genes 0.000 description 1
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 description 1
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LMEDOLJKVASKTP-UHFFFAOYSA-N dibutyl sulfate Chemical compound CCCCOS(=O)(=O)OCCCC LMEDOLJKVASKTP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- MZSJGCPBOVTKHR-UHFFFAOYSA-N isothiocyanatocyclohexane Chemical compound S=C=NC1CCCCC1 MZSJGCPBOVTKHR-UHFFFAOYSA-N 0.000 description 1
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明涉及使用对FKBP型亲免蛋白具有亲和性的低分子量、小分子氨基甲酸酯和脲影响神经元活动的药物组合物和方法。
Description
本申请是1997年2月27日提交的美国专利申请号08/805,646的部分继续申请,该申请的全部内容在此引作参考。
发明背景
1.发明领域
本发明涉及使用对FKBP型亲免蛋白具有亲和性的低分子量、小分子氨基甲酸酯和脲影响神经元活动(neuronal activity)的药物组合物和方法。
2.相关技术的描述
术语亲免蛋白是指许多用作主要免疫抑制药物、环孢菌素A(CsA)、FK506和雷帕霉素的受体的蛋白。已知类型的亲免蛋白是结合亲环蛋白和FK506的蛋白,或FKBPs。环孢菌素A与亲环蛋白A结合,而FK506和雷帕霉素与FKBP12结合。这些亲免蛋白-药物络合物邻接各种胞内信号传导系统,尤其是免疫和神经系统。
亲免蛋白已知具有肽基-葡氨酸异构酶(PPIase),或旋转异构酶,酶活性。已经确定旋转异构酶活性在用于亲免蛋白的肽和蛋白质基质的顺式和反式异构体相互转化的催化中起作用。
亲免蛋白最初在免疫组织中发现和研究。本领域熟练技术人员最初假定对亲免蛋白的旋转异构酶活性进行抑制导致对T细胞增殖的抑制,从而引起由免疫抑制药物如环孢菌素A、FK506和雷帕酶素显示的免疫抑制活性。进一步的研究表明对旋转异构酶活性的抑制本身并不产生免疫抑制活性。Schreiber等人,“科学”,1990,v.250,pp.556-559。相反,免疫抑制似乎源于免疫抑制药物与亲免蛋白络合物的形成。已经表明亲免蛋白-药物络合物与三元蛋白靶体以其作用模式相互作用。Schreiber等人,“细胞”,1991,v.66,pp.807-815。在FKBP-FK506和亲环蛋白-CsA情况下,亲免蛋白-药物络合物与酶钙神经素结合并抑制T细胞受体信号传导,这导致T细胞增殖。类似地,FKBP-雷帕酶素的亲免蛋白-药物络合物与RAFT1/FRAP蛋白相互作用并抑制IL-2受体信号传导。
已经发现亲免蛋白以高浓度存在于中枢神经系统中。亲免蛋白在中枢神经系统中比在免疫系统中富积10-50倍。在神经组织中,亲免蛋白似乎影响氧化氮合成、神经递质释放和神经元活动延长。
令人惊奇的是,已经发现某些对FKBPs具有高亲和性的低分子量、小分子氨基甲酸酯和脲显示出优异的神经营养作用。此外,这些化合物不具有免疫抑制活性。这些发现暗示了低分子量、小分子氨基甲酸酯和脲治疗各种外周神经病和增强中枢神经系统(CNS)中的神经元再生长的用途。研究表明神经变性疾病如阿尔茨海默氏病、帕金森氏病和肌萎缩性侧索硬化(ALS)可能因在该疾病中受感染的神经元的特定种群所特有的神经营养性物质丧失或其可用性降低而发生。
已经识别出几种影响中枢神经系统中的特定神经元种群的神经营养因子。例如,已经假设阿尔茨海默氏病源于神经生长因子(NGF)的降低或丧失。因此已建议用外源性神经生长因子或其它神经营养蛋白如脑衍生生长因子、胶质衍生生长因子、睫状神经营养因子和神经营养蛋白-3治疗SDAT患者,以增加变性神经元种群的存活。
这些蛋白在各种神经疾病状态中的临床应用因大蛋白向神经系统靶体的输送和生物利用率方面的困难而受阻。相反,具有神经营养活性的免疫抑制药物相对较小且显示优异的生物利用率和特异性。然而,当长期给药时,免疫抑制药物显示许多潜在的严重副作用,包括肾中毒性,如肾小球滤过受损和不可逆的间质纤维样变性(Kopp等人,J.Am.Soc.Nephrol.,1991,1:162);神经病性缺陷,如不随意震颤,或非特异性大脑绞痛,如非定域头痛(De Groen等人,N.Engl.J.Med.,1987,317:861);和带有由其引起的并发症的血管高血压(Kahan等人,N.Engl.J.Med.,1989,321:1725)。
为了防止与使用免疫抑制化合物有关的副作用,本发明的发明人提供了一种使用含有低分子量、小分子氨基甲酸酯和脲的非免疫抑制化合物的方法,以增强神经突长出并在各种其中神经元修复可以被促进的神经病理情形中促进神经元生长和再生,所述神经病理情形包括因物理损伤或疾病状态如糖尿病引起的外周神经损伤;对中枢神经系统(脊髓和脑)的物理损伤;与中风相关的脑损伤;和与神经变性相关的神经疾病,如帕金森氏病、SDAT(阿尔茨海默氏病)和肌萎缩性侧索硬化。
发明概述
本发明涉及使用对FKBP型亲免蛋白具有亲和性的神经营养性低分子量、小分子氨基甲酸酯和脲的方法。一旦与这些蛋白结合,这些神经营养化合物为与亲免蛋白有关的酶活性,特别是肽基-葡氨酸异构酶,或旋转异构酶,酶活性的有效抑制剂。这些神经营养化合物的关键特征在于它们不产生任何显著的免疫抑制活性。
具体而言,本发明涉及一种在动物中影响神经元活动的方法,包括:
向该动物给予非免疫抑制有效量的式Ⅰ化合物:或其可药用盐、酯或溶剂化物,其中:A为CH2,O或NR;R,B和D独立地为Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C5-C7环烷基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,C5-C7环烯基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,Ar取代的C1-C9直链或支链烷基或Ar取代的C2-C9直链或支链链烯基或炔基;其中所述烷基的任何碳原子任选被选自O、S、SO、SO2和NR3的杂原子替换;R3选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,和其中在所述含杂原子链的氮和碳原子之间形成桥以形成环且其中所述环任选与Ar基团稠合的C1-C9桥接烷基;J选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基和-CH2Ar;K选自C1-C9直链或支链烷基,-CH2Ar和环已基甲基;或J和K一起形成被O、S、SO或SO2取代的5-7元杂环;Z为O或S;Y为O或N,条件是当Y为O时,R1为孤对电子且R2选自Ar,C1-C9直链或支链烷基,和C2-C9直链或支链链烯基或炔基;和当Y为N时,R1和R2独立地选自Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C3-C7环烷基、环烯基或环炔基,C6-C14双环烷基、双环烯基或双环炔基,和C9-C21三环烷基、三环烯基或三环炔基;或R1和R2一起形成选自吡咯烷、咪唑烷、吡唑烷、哌啶和哌嗪的杂环5-6元环;Ar为碳环或杂环芳族部分,其未被取代或被一个或多个取代基取代;q为0-2;和n为0或1。
本发明还涉及一种在动物中影响神经元活动的方法,包括:向该动物给予非免疫抑制有效量的式Ⅱ或Ⅲ化合物或其可药用盐、酯或其溶剂化物,其中Y,R1,R2和Ar如式Ⅰ化合物中所定义;J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且w为1或2。
或其可药用盐、酯或其溶剂化物,其中
Y,R1,R2和Ar如式Ⅰ化合物中所定义;
J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且
w为1或2。
另外,本发明还涉及一种药物组合物,包含(ⅰ)非免疫抑制有效量的式Ⅰ化合物:或其可药用盐、酯或溶剂化物,其中:A为CH2,O或NR;R,B和D独立地为Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C5-C7环烷基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,C5-C7环烯基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,Ar取代的C1-C9直链或支链烷基或Ar取代的C2-C9直链或支链链烯基或炔基;其中所述烷基的任何碳原子任选被选自O、S、SO、SO2和NR3的杂原子替换;R3选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,和其中在所述含杂原子链的氮和碳原子之间形成桥以形成环且其中所述环任选与Ar基团稠合的C1-C9桥接烷基;J选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基和-CH2Ar;K选自C1-C9直链或支链烷基,-CH2Ar和环己基甲基;或J和K一起形成被O、S、SO或SO2取代的5-7元杂环;Z为O或S;Y为O或N,条件是当Y为O时,R1为孤对电子且R2选自Ar,C1-C9直链或支链烷基,和C2-C9直链或支链链烯基或炔基;和当Y为N时,R1和R2独立地选自Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C3-C7环烷基、环烯基或环炔基,C6-C14双环烷基、双环烯基或双环炔基,和C9-C21三环烷基、三环烯基或三环炔基;或R1和R2一起形成选自吡咯烷、咪唑烷、吡唑烷、哌啶和哌嗪的杂环5-6元环;Ar为碳环或杂环芳族部分,其未被取代或被一个或多个取代基取代;q为0-2;和n为0或1;和(ⅱ)可药用载体。
本发明还涉及一种药物组合物,包括(ⅰ)非免疫抑制有效量的用于影响神经元活动的式Ⅱ或Ⅲ化合物或其可药用盐、酯或其溶剂化物,其中Y,R1,R2和Ar如式Ⅰ化合物中所定义;J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且w为1或2;和(ⅱ)可药用载体。
本发明还涉及一种药物组合物,包括(ⅰ)非免疫抑制有效量的用于影响神经元活动的式Ⅱ’或Ⅲ化合物或其可药用盐、酯或其溶剂化物,其中Y,R1,R2和Ar如式Ⅰ化合物中所定义;J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且w为1或2;和(ⅱ)可药用载体。
本发明的方法和药物组合物影响神经元活动且特别是仅使用式Ⅰ,Ⅱ,Ⅱ’和Ⅲ的氨基甲酸酯和脲促进神经生长,而不需要任何其它神经营养性药物,包括神经营养生长因子。本发明的详细描述定义
“烷基”指含1-6个碳原子的支化或未支化的饱和烃链,如甲基,乙基,丙基,异丙基,丁基,异丁基,叔丁基,正戊基,正己基等,除非另有所指。
“环烷基”指其中各碳原子与两个相邻碳原子相连以形成环状结构的饱和烃链。本发明环烷基衍生物的非限制性例子是环丙基,环丁基,环戊基,环己基,环庚基和环辛基。“双环烷基”指其中两个或多个碳在两个烷基环结构之间共享的环烷基化合物。本发明的双环烷基衍生物的非限制性例子是双环戊烷,双环己,双环庚烷,双环辛烷,双环壬烷和双环癸烷。“三环烷基”指其中两个或多个碳在三个烷基环结构之间共享的环烷基化合物。本发明的三环烷基衍生物的非限制性例子是金刚烷基。本发明包括被与本发明烷基的取代基相同的本说明书前述部分取代的环烷基、双环烷基和三环烷基化合物。双环-和三环烷基化合物在本文也称为“稠合烷基环结构”。
“卤素”指氯,氟,溴或碘,除非另有所指。
“异构体”指具有相同数目和种类的原子且因此具有相同的分子量但原子的排列或构型不同的化合物。“立体异构体”指仅原子的空间排列不同的异构体。“对映体”是一对立体异构体,它们相互为不可重叠的镜像。“非对映异构体”是相互不呈镜像的立体异构体。“外消旋混合物”指含有等量单个对映体的混合物。“非外消旋混合物”是含有非等量单个对映体或立体异构体的混合物。
“可药用盐”指具有所需药理活性且既不在生理上也不在其它方面呈不利的主体化合物的盐。盐可以与无机酸形成,如乙酸盐,己二酸盐,藻酸盐,天冬氨酸盐,苯甲酸盐,苯磺酸盐,硫酸氢盐,丁酸盐,柠檬酸盐,樟脑酸盐,樟脑磺酸盐,环戊烷丙酸盐,二葡萄糖酸盐,十二烷基硫酸盐,乙磺酸盐,富马酸盐,葡庚糖酸盐,甘油磷酸盐,半硫酸盐(hemisulfate),庚酸盐,己酸盐,盐酸盐,氢溴酸盐,氢碘酸盐,2-羟基乙磺酸盐,乳酸盐,马来酸盐,甲磺酸盐,2-萘磺酸盐,烟酸盐,草酸盐,硫氰酸盐,甲苯磺酸盐和十一烷酸盐。碱盐包括铵盐,碱金属盐如钠和钾盐,碱土金属盐如钙和镁盐,与有机碱的盐,如二环己基胺盐,N-甲基-D-葡糖胺,以及与氨基酸如精氨酸、赖氨酸等的盐。还有,碱性含氮基团可以用诸如低级烷基卤如甲基、乙基、丙基和丁基的氯化物、溴化物和碘化物;硫酸二烷基酯如硫酸二甲酯、硫酸二乙酯、硫酸二丁酯和硫酸二戊酯;长链卤化物如癸基、十二烷基、十四烷基和硬脂基的氯化物、溴化物和碘化物;芳烷基卤化物如苄基和苯乙基的溴化物以及其它物质等试剂季铵化。由此得到水或油溶性或分散性产品。
“治疗”指:(ⅰ)防止疾病和/或症状在易患该疾病和/或症状但还未确诊的主体中发生;(ⅱ)抑制该疾病和/或症状,即阻止其发展;和(ⅲ)缓解该疾病和/或症状,即使该疾病和/或症状消退。本发明的方法
本发明的发明人发现某些低分子量、小分子氨基甲酸酯和脲对FKBP型亲免蛋白,特别是对FKBP12具有亲和性。当氨基甲酸酯和脲结合于FKBP型亲免蛋白时,发现它们抑制结合蛋白的肽基-脯氨酸顺-反异构酶活性,或旋转异构酶活性。出人意料的是,已经发现这些非免疫抑制化合物还刺激神经突生长。该活性可以用于刺激受损的神经元,促进神经元再生,预防神经变性和治疗几种已知与神经元变性和外周神经病有关的神经疾病。
由于前述原因,本发明涉及一种在动物中影响神经元活动的方法,包括对该动物给予非免疫抑制有效量的式Ⅰ化合物:或其可药用盐、酯或溶剂化物,其中:A为CH2,O或NR;R,B和D独立地为Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C5-C7环烷基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,C5-C7环烯基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,Ar取代的C1-C9直链或支链烷基或Ar取代的C2-C9直链或支链链烯基或炔基;其中所述烷基的任何碳原子任选被选自O、S、SO、SO2和NR3的杂原子替换;R3选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,和其中在所述含杂原子链的氮和碳原子之间形成桥以形成环且其中所述环任选与Ar基团稠合的C1-C9桥接烷基;J选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基和-CH2Ar;K选自C1-C9直链或支链烷基,-CH2Ar和环已基甲基;或J和K一起形成被O、S、SO或SO2取代的5-7元杂环;Z为O或S;Y为O或N,条件是当Y为O时,R1为孤对电子且R2选自Ar,C1-C9直链或支链烷基,和C2-C9直链或支链链烯基或炔基;和当Y为N时,R1和R2独立地选自Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C3-C7环烷基、环烯基或环炔基,C6-C14双环烷基、双环烯基或双环炔基,和C9-C21三环烷基、三环烯基或三环炔基;或R1和R2一起形成选自吡咯烷、咪唑烷、吡唑烷、哌啶和哌嗪的杂环5-6元环;Ar为碳环或杂环芳族部分,其未被取代或被一个或多个取代基取代;q为0-2;和n为0或1。
在优选的实施方案中,J和K一起形成5-7元杂环。
在另一优选的实施方案中,Ar选自苯基,1-萘基,2-萘基,茚基,甘菊环基,芴基和蒽基;或选自如下的杂环:2-呋喃基,3-呋喃基,2-噻吩基,3-噻吩基,2-吡啶基,3-吡啶基,4-吡啶基,吡咯基,噁唑基,噻唑基,咪唑基,吡唑基(pyraxolyl),2-吡唑啉基,吡唑烷基,异噁唑基,异三唑基,1,2,3-噁二唑基,1,2,3-三唑基,1,3,4-噻二唑基,哒嗪基,嘧啶基,吡嗪基,1,3,5-三嗪基,1,3,5-三噻烷基,中氮茚基,吲哚基,异氮杂茚基,3H-吲哚基,二氢吲哚基,苯并[b]呋喃基,苯并[b]噻吩基,1H-吲唑基,苯并咪唑基,苯并噻唑基,嘌呤基,4H-喹嗪基,喹啉基,1,2,3,4-四氢喹啉基,异喹啉基,1,2,3,4-四氢异喹啉基,肉啉基,2,3-二氮杂萘基,喹唑啉基,喹喔啉基,1,8-二氮杂萘基,蝶啶基,咔唑基,吖啶基,吩嗪基,吩噻嗪基和吩噁嗪基;其中Ar是未取代的或被一个或多个取代基取代,所述取代基独立地选自卤素、羟基、硝基、-SO3H、三氟甲基、三氟甲氧基、C1-C9直链或支链烷基、C2-C9直链或支链链烯基、O-(C1-C9直链或支链烷基)、O-(C2-C9直链或支链链烯基)、O-苄基、O-苯基、1,2-亚甲二氧基、-NR4R5、羧基、N-(C1-C9直链或支链烷基或C2-C9直链或支链链烯基)羧酰胺、N,N-二-(C1-C9直链或支链烷基或C2-C9直链或支链链烯基)羧酰胺、吗啉基、哌啶基、O-X、CH2-(CH2)q-X、O-(CH2)q-X、(CH2)q-O-X和CH=CH-X;R4和R5独立地选自C1-C9直链或支链烷基,C2-C9直链或支链链烯基,氢和苄基;或R4和R5一起形成5-6元杂环;和X选自4-甲氧基苯基,2-吡啶基,3-吡啶基,4-吡啶基,吡唑基(pyrazyl),喹啉基,3,5-二甲基异噁唑基,异噁唑基,2-甲基噻唑基,噻唑基,2-噻吩基,3-噻吩基和嘧啶基。
在另一个优选的实施方案中,所述B和D中至少一个独立地由式-(CH2)r-(X’)-(CH2)s-Ar所代表,其中r为1-4;s为0-1;和各X’独立地选自CH2、O、S、SO、SO2和NR6,其中R6选自氢、C1-C9直链或支链烷基、C2-C9直链或支链链烯基或炔基和其中在氮原子和Ar之间形成桥的C1-C9桥接烷基。
在再一个优选的实施方案中,Ar选自苯基,2-吡啶基,3-吡啶基,4-吡啶基,吲哚基,异氮杂茚基,喹啉基,异喹啉基,1,2,3,4-四氢异喹啉基和1,2,3,4-四氢喹啉基,其中所述Ar为未取代的或被一个或多个取代基取代,所述取代基独立地选自羟基、硝基、三氟甲基、C1-C9直链或支链烷基、O-(C1-C9直链或支链烷基)、卤素、SO3H和NR4R5;和R4和R5独立地选自C1-C9直链或支链烷基,C2-C9直链或支链链烯基,氢和苄基;或R4和R5一起形成5-7元杂环。
在又一个优选实施方案中,Y为N,和
R1和R2独立地选自氢、C3-C7环烷基、C6-C14双环烷基和C9-C21三环烷基。
在最优选的实施方案中,该化合物为(2S)-1-[(2-甲基丁基)-氨基甲酰基1吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯,(2S)-1-[(1’,1’-二甲基丙基)-氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯,(2S)-1-[(环已基)硫代氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯,(2S)-1-[(环已基)氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯,或(2S)-1-[(1-金刚烷基)-硫代氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
本发明还涉及一种在动物中影响神经元活动的方法,包括
对该动物给予非免疫抑制有效量的式Ⅱ或Ⅲ化合物或其可药用盐、酯或其溶剂化物,其中Y,R1和R2如权利要求1所定义;Ar如权利要求8所定义;J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且w为1或2。
本发明还涉及一种在动物中影响神经元活动的方法,包括
对该动物给予非免疫抑制有效量的式Ⅱ’或Ⅲ化合物或其可药用盐、酯或其溶剂化物,其中Y,R1和R2如权利要求1所定义;Ar如权利要求8所定义;J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且w为1或2。
通过本发明的方法影响的神经元活动可以选自对受损神经元的刺激、神经元再生的促进、神经变性的预防和神经疾病的治疗。
可以由本发明方法治疗的神经疾病的实例包括但不限于:三叉神经痛;舌咽神经痛;面神经麻痹;重症肌无力;肌肉营养不良;肌萎缩性侧索硬化;进行性肌萎缩;进行性延髓遗传肌萎缩;成疝的、破裂的或脱垂的无脊椎盘综合征;颈椎骨脱离;神经丛疾病;胸输出破坏综合征;外周神经病如由铅、氨苯砜、蜱、紫质症或急性感染性多神经炎引起的那些;阿尔茨海默氏病和帕金森氏病。
本发明的方法特别可以用于治疗选自如下的神经疾病:由物理损伤或疾病状态引起的外周神经病、脑的物理损伤、脊髓的物理损伤、与脑损伤有关的中风和与神经变性有关的神经疾病。与神经变性有关的神经疾病选自阿尔茨海默氏病、帕金森氏病和肌萎缩性侧索硬化。
在本发明的方法中,神经营养化合物可以口服给药、肠胃外给药、通过吸入喷雾给药、局部给药、直肠给药、经鼻给药、经颊给药、经阴道给药或以含常规无毒可药用载体、助剂和赋形剂的剂型经植入的容器给药。本文所用的术语肠胃外包括皮下、静脉内、肌内、腹膜内、鞘内、心室内、胸骨内和颅内注射或输注技术。
为了作为中枢神经系统靶体在治疗上有效,神经营养化合物应在外周给药时易于穿透血-脑屏障。不能穿透血-脑屏障的化合物可以通过心室内途径有效给药。
神经营养化合物还可以无菌的可注射制剂形式给药,例如以无菌可注射的水或油悬浮液。这些悬浮液可以按照本领域已知的技术使用合适的分散或润温剂和悬浮剂配制。无菌可注射制剂还可以是在无毒肠胃外可接受的稀释剂或溶剂中的无菌可注射溶液或悬浮液,例如在1,3-丁二醇中的溶液。可以使用的可接受赋形剂和溶剂有水,林格溶液和等渗氯化钠溶液。此外,无菌的固定油常用作溶剂或悬浮介质。为此,可以使用任何刺激性少的固定油如合成的甘油单酯或甘油二酯。脂肪酸如油酸及其甘油酯衍生物,包括橄榄油和蓖麻油,尤其是其聚氧乙基化形式,可以用于制备可注射液。这些油溶液或悬浮液还可以含有长链醇稀释剂或分散剂。
另外,神经营养化合物可以胶囊、片剂、水悬浮液或溶液形式口服给药。片剂可以含有载体如乳糖和玉米淀粉,和/或润滑剂如硬脂酸镁。胶囊可以含有稀释剂,包括乳糖和干燥的玉米淀粉。水悬浮液可以含有与活性成分混合的乳化剂和悬浮剂。口服剂型还可以含有甜味剂和/或调味剂和/或着色剂。
神经营养化合物还可以栓剂形式直肠给药。这些组合物可以通过将药物与合适的非刺激性赋形剂混合而制备,所述赋形剂在室温下为固体但在直肠温度下为液体且因此在直肠内融化而释放出药物。该类材料包括可可脂、蜂蜡和聚乙二醇。
此外,神经营养化合物可以局部给药,尤其在待治疗症状涉及易于通过局部用药接近的区域或器官时,所述症状包括眼睛、皮肤或下肠道的神经疾病。合适的局部剂型易于对各种这些区域进行制备。
对于眼睛的局部用药,或眼科应用,化合物可以在等渗的pH已调的无菌盐水中配制成微粒化的悬浮液,或优选在等渗的pH已调的无菌盐水中的溶液,含有或不含有防腐剂如氯苄烷铵。另外,化合物可以配制成油膏,如凡士林,用于眼科。
对于皮肤的局部用药,化合物可以配制成含有悬浮或溶于例如下列物质中的一种或多种中的化合物的合适油膏:矿物油、液态石蜡、白凡士林、丙二醇、聚氧乙烯聚氧丙烯化合物,乳化蜡和水。另外,化合物可以配制成含有悬浮或溶于例如下列物质中的一种或多种中的活性化合物的合适洗剂或霜剂:矿物油、脱水山梨糖醇单硬脂酸酯、多乙氧基醚60、鲸蜡基酯蜡、鲸蜡醇(cetearyl alcohol)、2-辛基十二烷醇、苄醇和水。
下肠道的局部用药可以直肠栓剂制剂形式(见上述)进行或以合适的灌肠制剂进行。
约为0.1mg-约10,000mg活性成分化合物的剂量水平可用于治疗上述症状,优选的水平为约0.1mg-约1,000mg。可以与载体材料混合以生产单一剂型的活性成分量随治疗的宿主和具体给药模式而改变。
然而应该理解的是对于任何特定患者,具体的剂量水平取决于各种因素,包括所用具体化合物的活性;患者的年龄、体重、总体健康状况、性别和饮食;给药时间;排泄速率;药物联合;待治疗的特定疾病的严重程度;以及给药方式。
化合物可以单独或与其他神经营养药物如神经营养生长因子(NGF)、胶质衍生生长因子、脑衍生生长因子、睫状神经营养因子和神经营养蛋白-3一起给药。其他神经营养药物的剂量水平取决于前述因素和药物联合的神经营养有效性。本发明的药物组合物
另外,本发明涉及一种药物组合物,包含(i)非免疫抑制有效量的式Ⅰ化合物:或其可药用盐、酯或溶剂化物,其中:A为CH2,O或NR;R,B和D独立地为Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C5-C7环烷基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,C5-C7环烯基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,Ar取代的C1-C9直链或支链烷基或Ar取代的C2-C9直链或支链链烯基或炔基;其中所述烷基的任何碳原子任选被选自O、S、SO、SO2和NR3的杂原子替换;R3选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,和其中在所述含杂原子链的氮和碳原子之间形成桥以形成环且其中所述环任选与Ar基团稠合的C1-C9桥接烷基;J选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基和-CH2Ar;K选自C1-C9直链或支链烷基,-CH2Ar和环已基甲基;或J和K一起形成被O、S、SO或SO2取代的5-7元杂环;Z为O或S;Y为O或N,条件是当Y为O时,R1为孤对电子且R2选自Ar,C1-C9直链或支链烷基,和C2-C9直链或支链链烯基或炔基;和当Y为N时,R1和R2独立地选自Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C3-C7环烷基、环烯基或环炔基,C6-C14双环烷基、双环烯基或双环炔基,和C9-C21三环烷基、三环烯基或三环炔基;或R1和R2一起形成选自吡咯烷、咪唑烷、吡唑烷、哌啶和哌嗪的杂环5-6元环;Ar为碳环或杂环芳族部分,其未被取代或被一个或多个取代基取代;q为0-2;和n为0或1;和(ⅱ)可药用载体。
本发明还涉及一种药物组合物,包括(ⅰ)非免疫抑制有效量的用于影响神经元活动的式Ⅱ或Ⅲ化合物或其可药用盐、酯或其溶剂化物,其中Y,R1和R2如权利要求21所定义;Ar如权利要求28所定义;J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且w为1或2;和(ⅱ)可药用载体。
本发明还涉及一种药物组合物,包括(ⅰ)非免疫抑制有效量的用于影响神经元活动的式Ⅱ’或Ⅲ化合物或其可药用盐、酯或其溶剂化物,其中Y,R1和R2如权利要求21所定义;Ar如权利要求28所定义;J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且w为1或2;和(ⅱ)可药用载体。
优选的神经元活动和式Ⅰ、Ⅱ、Ⅱ’和Ⅲ化合物如前面对本发明方法所述。
用于本发明方法和药物组合物中的化合物具有一个或多个不对称中心且因此可以立体异构体的混合物(外消旋和非外消旋)或以单个的R-和S-立体异构体生产。单个的立体异构体可以通过使用旋光活性原料、通过在合成的某些合适阶段拆分中间体的外消旋或非外消旋混合物或通过拆分式Ⅰ化合物而得到。除非另有所指,用于本发明方法和药物组合物中的化合物包括单个的立体异构体以及立体异构体的混合物(外消旋和非外消旋)。
实施例
下列实施例说明本发明且并不意欲限制本发明。除非另有规定,所有百分数均基于最终化合物的100%重量。
用于本发明方法和药物组合物中的化合物可以通过有机化学的标准技术使用下述通用合成路线而容易地制备。如方案Ⅰ所示,通过合适的封闭基团P在氨基酸氮上保护的环状氨基酸1可以与醇ROH反应,产生酯2。除去保护基团后,游离胺3可以与各种异氰酸酯或异硫氰酸酯反应,分别得到最终的脲或硫脲。另外,1与胺的反应得到相应的酰胺化合物。
异氰酸酯(R1NCO)或异硫氰酸酯(R1NCS)4可以通过与光气或硫光气如方案Ⅱ反应而方便地由相应的易得胺制备。
实施例1
合成(2S)-1-[(2-甲基丁基)氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(1)
(2S)-N-(叔丁氧基羰基)吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯
将N-(叔丁氧基羰基)-(S)-脯氨酸(3.0g;13.9mmol)、3-(3-吡啶基)-1-丙醇(2.90g;20.9mmol)、二环已基碳二亚胺(4.59g;22.24mmol)、樟脑磺酸(1.08g;4.63mmol)和4-二甲氨基吡啶(0.60g;4.63mmol)在无水二氯甲烷(100ml)中的混合物搅拌一夜。将反应混合物用二氯甲烷(50ml)和水(100ml)稀释,并分离各层。有机层用水洗涤(3×100ml),用硫酸镁干燥并浓缩,粗残余物在硅胶柱上提纯,用乙酸乙酯洗脱,得到4.60g(95%)的酯,为浓稠油形式,1H NMR(300MHz,CDCl3):δ1.45(s,9H);1.70-2.05(m,5H);2.32(m,1H);2.71(t,2H);3.50(m,2H);4.15(m,2H);4.18(m,1H);7.24(m,1H);7.51(m,1H);8.48(m,2H)。
吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯
将(2S)-N-(叔丁氧基羰基)吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(3.0g;9mmol)在二氯甲烷(50ml)和三氟乙酸(5ml)中的溶液室温搅拌3小时。加入饱和碳酸钾直到pH呈碱性,将反应混合物用二氯甲烷萃取(3×)。干燥合并的有机萃取液并浓缩,得到2.00g(95%)游离胺,为浓稠油。1H NMR(300MHz,CDCl3):δ1.87-2.20(m,6H);2.79(m,2H);3.03(m,总共2H);3.07(m,2H);3.84(m,1H);4.24(m,2H);7.32(m,1H);7.60(m,1H);8.57(m,2H)。
(2S)-1-[(2-甲基丁基)氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(1)
将2-甲基丁基胺(113mg;1.3mmol)和三乙胺(132mg;1.3mmol)的二氯甲烷(5ml)溶液加入三光气(128mg;0.43mmol)的二氯甲烷(5ml)溶液中。将所得混合物回流1小时,然后冷却至室温。加入5ml二氯甲烷中的(2S)-吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(300mg;1.3mmol)并将所得混合物搅拌1小时,然后在水和乙酸乙酯与己烷的1∶1混合物之间分配。干燥有机相,浓缩并通过柱色谱(50%乙酸乙酯/己烷)提纯,得到250mg(55%)实施例1的化合物(1,表Ⅰ),为油状物。1H NMR(300MHz,CDCl3):δ0.89-0.93(m,6H);1.10-1.20(m,1H);1.27(s,1H);1.36-1.60(m,2H);1.72(s,2H);1.97-2.28(m,6H);2.70-2.75(m,2H);2.92-3.54(m,4H);4.16-4.20(dt,2H);4.45-4.47(m,2H);7.21-7.29(m,1H);7.53-7.56(dd,1H);8.46-8.48(s,2H)。C19H29N3O3-0.5H2O的分析计算值:C,64.02;H,8.48;N,11.79。实测值:C,63.72;H,8.42;N,11.83。
实施例2
合成(2S)-1-[(1’,1’-二甲基丙基)氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(2)
如实施例1所述使(2S)-吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯与由叔戊基胺和三光气产生的异氰酸酯反应,得到实施例2的化合物(2,表Ⅰ),产率为62%。1H NMR(300MHz,CDCl3):δ0.83(t,3H);1.27(s,6H);1.64-1.71(m,2H);1.91-2.02(m,7H);2.66-2.71(t,2H);3.29-3.42(m,2H);4.11-4.15(t,3H);4.37-4.41(m,1H)。C19H29N3O3-0.5H2O的分析计算值:C,64.04;H,8.48;N,11.79。实测值:C,64.23;H,8.31;N,11.30。
实施例3
合成(2S)-1-[(环己基)硫代氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(3)
将异硫氰酸环己基酯(120mg;0.9mmol)、(2S)-吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(200mg;0.9mmol)和三乙胺(90mg;0.9mmol)在20ml二氯甲烷中的混合物搅拌1小时,然后在水和乙酸乙酯与己烷的1∶1混合物之间分配。干燥有机相,浓缩并通过柱色谱(50%乙酸乙酯/己烷)提纯,得到160mg(47%)实施例3的化合物(3,表Ⅰ),1H NMR(300MHz,CDCl3):δ1.16-1.40(m,6H);1.50-1.71(m,4H);1.95-2.08(m,7H);2.70-2.75(t,2H);3.40-3.60(m,2H);4.17-4.26(m,2H);4.95-4.98(d,1H);5.26-5.29(d,1H);7.17-7.25(m,1H)。C20H29N3O2S的分析计算值:C,63.97;H,7.78;N,11.19。实测值:C,63.25;H,7.80;N,11.07。
实施例4
合成(2S)-1-[(环己基)氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(4)
将异氰酸环己基酯(100mg;0.9mmol)、(2S)-吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(200mg;0.9mmol)和三乙胺(90mg;0.9mmol)在20ml二氯甲烷中的混合物搅拌1小时,然后在水和乙酸乙酯与已烷的1∶1混合物之间分配。干燥有机相,浓缩并通过柱色谱(50%乙酸乙酯/己烷)提纯,得到120mg(36%)实施例4的化合物(4,表Ⅰ),1H NMR(300MHz,CDCl3):δ1.10-1.27(m,6H);1.69-1.75(m,4H);1.94-2.03(m,4H);2.67-2.73(t,2H);3.31-3.44(m,3H);4.12-4.16(m,2H);4.39-4.45(m,1H);7.25-7.34(m,1H);7.25-7.55(dd,1H);8.45(s,2H)。C20H29N3O3-0.6H2O的分析计算值:C,64.88;H,8.22;N,11.35.实测值:C,64.60;H,8.18;N,11.21。
实施例5
合成(2S)-1-[(1-金刚烷基)硫代氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(5)
将异硫氰酸1-金刚烷基酯(250mg;0.9mmol)、(2S)-吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯(200mg;0.9mmol)和三乙胺(90mg;0.9mmol)在20ml二氯甲烷中的混合物搅拌1小时,然后在水和乙酸乙酯与己烷的1∶1混合物之间分配。干燥有机相,浓缩并通过柱色谱(50%乙酸乙酯/己烷)提纯,得到150mg(38%)实施例4的化合物(4,表Ⅰ),1H NMR(300MHz,CDCl3):δ1.39-1.44(d,2H);1.65(s,4H);1.95-2.07(m,8H);2.07-2.20(m,5H);2.71-2.76(m,2H);3.37-3.45(m,1H);3.50-3.60(m,1H);4.09-4.18(m,2H);4.99-5.21(d,1H);7.21-7.25(m,1H)。C24H33N3O2S-0.4H2O的分析计算值:C,66.30;H,7.84;N,9.66。实测值:C,66.41;H,7.79;N,9.50。
如上所述,用于本发明方法和药物组合物中的氨基甲酸酯和脲对FK506结合蛋白,特别是FKBP12具有亲和性。FKBP的肽基脯氨酸顺-反异构酶活性的抑制可以作为该亲和性的指示来测定。Ki测试程序
本发明化合物对肽基脯氨酸异构酶(旋转异构酶)活性的抑制可通过文献(Harding等人,自然,1989,341:758-760;Holt等人,美国化学会会志,115:9923-9938)所述的已知方法评价。这些值以表观Ki得到且示于表Ⅱ中。丙氨酸-脯氨酸键在模型基质N-琥珀酰-Ala-Ala-Pro-Phe-对硝基酰苯胺(p-nitroanilide)中的顺-反异构化在胰凝乳蛋白酶偶合分析中以分光光度计法检测,其从反式基质释放对硝基酰苯胺。测定通过加入不同浓度的抑制剂而引起的对该反应的抑制,并以一级速率常数随抑制剂浓度的变化分析数据,得到表观Ki值。
在塑料小池中加入950ml冰冷的分析缓冲液(25mM HEPES,pH7.8,100mM NaCl)、10mlFKBP(2.5mM,在10mM Tris-ClpH7.5中,100mM NaCl,1mM二硫苏糖醇)、25ml胰凝乳蛋白酶(50mg/ml,在1mM HCl中)和10ml在二甲亚砜中的不同浓度试验化合物。通过加入5ml基质(琥珀酰-Ala-Phe-Pro-Phe-对硝基酰苯胺,5mg/ml,在2.35mM LiCl的三氟乙醇溶液中)而引发反应。
使用分光光度计监测390nm下的吸光度对时间90秒并由吸光度对时间数据文件确定速率常数。
对代表性化合物所进行的这些试验的数据示于表Ⅱ的“Ki”栏中。
用于本发明方法和药物组合物中的氨基甲酸酯和脲的神经营养效应可以在如下所述的体外细胞生物学试验中显示。小鸡后根神经节培养物和神经突长出
从发育十天的小鸡胚胎切除后根神经节。将整个神经节外植体在薄层Matrigel涂敷的12孔板上用Liebovitz加高葡萄糖培养基在37℃和含5%CO2的环境中培养,该培养基补充有2mM谷氨酰胺和10%胎牛血清且还含有10μM胞嘧啶β-D阿拉伯呋喃糖(Ara C)。24小时后,用各种亲免蛋白配体处理DRG。药物处理48小时后,将神经节在相差或Hoffman调制反衬下用Zeiss Axiovert倒置显微镜观察。制备外植体的显微相片并定量神经突长出。将长于DRG直径的神经突记为正,按各试验条件定量神经突的总数。每孔培养3-4个DRG且每次处理进行2次。
对代表性化合物进行的这些试验的数据示于表Ⅱ的“ED50”栏中。
表Ⅰ
实施例序号 m Z n D B R1 R21 1 O 2 3-吡啶基 H 2-甲基丁基 H2 1 O 2 3-吡啶基 H 1,1-二甲基丙基 H3 1 S 2 3-吡啶基 H 环已基 H4 1 O 2 3-吡啶基 H 环已基 H5 1 S 2 3-吡啶基 H 1-金刚烷基 H
表Ⅱ
实施例化合物的体外活性
实施例号 Ki,nM ED50,nM
1 70 0.065
2 742 1
3 131 0.292
4 1482 未测
5 116 0.141
帕金森氏病的MPTP模型
本发明化合物的显著神经营养和神经变性作用进一步显示在神经变性疾病的动物模型中。将小鼠中的多巴胺能神经元的MPTP损伤用作帕金森氏病的动物模型。对四周龄的雄性CD1白鼠腹膜内给予30mg/kg的MPTP5天。将试验化合物(4mg/kg)或赋形剂与MPTP一起皮下给药5天,并在停止MPTP处理后再给药5天。MPTP处理18天后,将动物处死并将纹状体切出和灌注固定。在矢状和冠状脑切面上使用抗酪氨酸羟化酶1g进行免疫染色以定量多巴胺能神经元的存活和恢复。在用MPTP和赋形剂处理的动物中,与未损伤的动物相比,观察到功能性多巴胺能末端显著丧失。接受试验化合物的损伤动物显示显著的TH染色多巴胺能神经元恢复。表Ⅲ提供了在该模型中TH阳性多巴胺能神经元在接受化合物1,2,5和6的动物的纹状体中恢复的定量结果。
表Ⅲ
实施例化合物的体外活性
实施例号 TH免疫染色的恢复%,4mg/kg s.c.
1 27.47
2 未测
3 56.13
4 59.79
5 52.32
上面所提到的所有出版物和专利均在此引作参考。
本发明已经在此进行了描述,但显然本发明可以许多方式加以改变。这些改变不应认为偏离本发明的要旨和范围且所有这些改变意欲包括在下列权利要求的范围内。
Claims (44)
1.一种在动物中影响神经元活动的方法,包括:
向该动物给予非免疫抑制有效量的式Ⅰ化合物:或其可药用盐、酯或溶剂化物,其中:A为CH2,O或NR;R,B和D独立地为Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C5-C7环烷基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,C5-C7环烯基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,Ar取代的C1-C9直链或支链烷基或Ar取代的C2-C9直链或支链链烯基或炔基;其中所述烷基的任何碳原子任选被选自O、S、SO、SO2和NR3的杂原子替换;R3选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,和其中在所述含杂原子链的氮和碳原子之间形成桥以形成环且其中所述环任选与Ar基团稠合的C1-C9桥接烷基;J选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基和-CH2Ar;K选自C1-C9直链或支链烷基,-CH2Ar和环己基甲基;或J和K一起形成被O、S、SO或SO2取代的5-7元杂环;Z为O或S;Y为O或N,条件是当Y为O时,R1为孤对电子且R2选自Ar,C1-C9直链或支链烷基,和C2-C9直链或支链链烯基或炔基;和当Y为N时,R1和R2独立地选自Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C3-C7环烷基、环烯基或环炔基,C6-C14双环烷基、双环烯基或双环炔基,和C9-C21三环烷基、三环烯基或三环炔基;或R1和R2一起形成选自吡咯烷、咪唑烷、吡唑烷、哌啶和哌嗪的杂环5-6元环;Ar为碳环或杂环芳族部分,其未被取代或被一个或多个取代基取代;q为0-2;和n为0或1。
2.根据权利要求1的方法,其中神经元活动选自对受损神经元的刺激、神经元再生的促进、神经变性的预防和神经疾病的治疗。
3.根据权利要求2的方法,其中神经疾病选自由物理损伤或疾病状态引起的外周神经病、脑的物理损伤、脊髓的物理损伤、与脑损伤有关的中风和与神经变性有关的神经疾病。
4.根据权利要求3的方法,其中与神经变性有关的神经疾病选自阿尔茨海默氏病、帕金森氏病和肌萎缩性侧索硬化。
5.根据权利要求1的方法,其中J和K一起形成5-7元环。
6.根据权利要求1的方法,Ar选自苯基,1-萘基,2-萘基,茚基,甘菊环基,芴基和蒽基;或选自如下的杂环:2-呋喃基,3-呋喃基,2-噻吩基,3-噻吩基,2-吡啶基,3-吡啶基,4-吡啶基,吡咯基,噁唑基,噻唑基,咪唑基,吡唑基,2-吡唑啉基,吡唑烷基,异噁唑基,异三唑基,1,2,3-噁二唑基,1,2,3-三唑基,1,3,4-噻二唑基,哒嗪基,嘧啶基,吡嗪基,1,3,5-三嗪基,1,3,5-三噻烷基,中氮茚基,吲哚基,异氮杂茚基,3H-吲哚基,二氢吲哚基,苯并[b]呋喃基,苯并[b]噻吩基,1H-吲唑基,苯并咪唑基,苯并噻唑基,嘌呤基,4H-喹嗪基,喹啉基,1,2,3,4-四氢喹啉基,异喹啉基,1,2,3,4-四氢异喹啉基,肉啉基,2,3-二氮杂萘基,喹唑啉基,喹喔啉基,1,8-二氮杂萘基,蝶啶基,咔唑基,吖啶基,吩嗪基,吩噻嗪基和吩噁嗪基;其中Ar是未取代的或被一个或多个取代基取代,所述取代基独立地选自卤素、羟基、硝基、-SO3H、三氟甲基、三氟甲氧基、C1-C9直链或支链烷基、C2-C9直链或支链链烯基、O-(C1-C9直链或支链烷基)、O-(C2-C9直链或支链链烯基)、O-苄基、O-苯基、1,2-亚甲二氧基、-NR4R5、羧基、N-(C1-C9直链或支链烷基或C2-C9直链或支链链烯基)羧酰胺、N,N-二-(C1-C9直链或支链烷基或C2-C9直链或支链链烯基)羧酰胺、吗啉基、哌啶基、O-X、CH2-(CH2)q-X、O-(CH2)q-X、(CH2)q-O-X和CH=CH-X;R4和R5独立地选自C1-C9直链或支链烷基,C2-C9直链或支链链烯基,氢和苄基;或R4和R5一起形成5-6元杂环;和
X选自4-甲氧基苯基,2-吡啶基,3-吡啶基,4-吡啶基,吡唑基,喹啉基,3,5-二甲基异噁唑基,异噁唑基,2-甲基噻唑基,噻唑基,2-噻吩基,3-噻吩基和嘧啶基。
7.根据权利要求1的方法,其中所述B和D中至少一个独立地由式-(CH2)r-(X’)-(CH2)s-Ar所代表,其中r为1-4;s为0-1;和各X’独立地选自CH2、O、S、SO、SO2和NR6,其中R6选自氢、C1-C9直链或支链烷基、C2-C9直链或支链链烯基或炔基和其中在氮原子和Ar之间形成桥的C1-C9桥接烷基。
8.根据权利要求1的方法,其中Ar选自苯基,2-吡啶基,3-吡啶基,4-吡啶基,吲哚基,异氮杂茚基,喹啉基,异喹啉基,1,2,3,4-四氢异喹啉基和1,2,3,4-四氢喹啉基,其中所述Ar为未取代的或被一个或多个取代基取代,所述取代基独立地选自羟基、硝基、三氟甲基、C1-C9直链或支链烷基、O-(C1-C9直链或支链烷基)、卤素、SO3H和NR4R5和R4和R5独立地选自C1-C9直链或支链烷基,C2-C9直链或支链链烯基,氢和苄基;或R4和R5一起形成5-7元杂环。
9.根据权利要求1的方法,其中Y为N,和R1和R2独立地选自氢、C1-C9直链或支链烷基、C2-C9直链或支链链烯基或炔基、C3-C7环烷基、C6-C14双环烷基和C9-C21三环烷基。
10.根据权利要求9的方法,其中该化合物为(2S)-1-[(2-甲基丁基)-氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
11.根据权利要求9的方法,其中该化合物为(2S)-1-[(1’,1’-二甲基丙基)-氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
12.根据权利要求9的方法,其中该化合物为(2S)-1-[(环已基)硫代氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
13.根据权利要求9的方法,其中该化合物为(2S)-1-[(环己基)氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
14.根据权利要求9的方法,其中该化合物为(2S)-1-[(1-金刚烷基)-硫代氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
16.根据权利要求15的方法,其中神经元活动选自对受损神经元的刺激、神经元再生的促进、神经变性的预防和神经疾病的治疗。
17.根据权利要求16的方法,其中神经疾病选自由物理损伤或疾病状态引起的外周神经病、脑的物理损伤、脊髓的物理损伤、与脑损伤有关的中风和与神经变性有关的神经疾病。
18.根据权利要求17的药物组合物,其中与神经变性有关的神经疾病选自阿尔茨海默氏病、帕金森氏病和肌萎缩性侧索硬化。
19.一种在动物中影响神经元活动的方法,包括对该动物给予非免疫抑制有效量的式Ⅱ’或Ⅲ化合物或其可药用盐、酯或其溶剂化物,其中Y,R1和R2如权利要求1所定义;Ar如权利要求8所定义;J为氢、C1-C9直链或支链烷基或C2-C9直链或支链链烯基;且w为1或2。
20.根据权利要求19的方法,其中神经元活动选自对受损神经元的刺激、神经元再生的促进、神经变性的预防和神经疾病的治疗。
21.根据权利要求20的方法,其中神经疾病选自由物理损伤或疾病状态引起的外周神经病、脑的物理损伤、脊髓的物理损伤、与脑损伤有关的中风和与神经变性有关的神经疾病。
22.根据权利要求21的方法,其中与神经变性有关的神经疾病选自阿尔茨海默氏病、帕金森氏病和肌萎缩性侧索硬化。
23.一种药物组合物,包含(ⅰ)非免疫抑制有效量的式Ⅰ化合物:或其可药用盐、酯或溶剂化物,其中:A为CH2,O或NR;R,B和D独立地为Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C5-C7环烷基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,C5-C7环烯基取代的C1-C9直链或支链烷基或C2-C9直链或支链链烯基或炔基,Ar取代的C1-C9直链或支链烷基或Ar取代的C2-C9直链或支链链烯基或炔基;其中所述烷基的任何碳原子任选被选自O、S、SO、SO2和NR3的杂原子替换;R3选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,和其中在所述含杂原子链的氮和碳原子之间形成桥以形成环且其中所述环任选与Ar基团稠合的C1-C9桥接烷基;J选自氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基和-CH2Ar;K选自C1-C9直链或支链烷基,-CH2Ar和环已基甲基;或J和K一起形成被O、S、SO或SO2取代的5-7元杂环;Z为O或S;Y为O或N,条件是当Y为O时,R1为孤对电子且R2选自Ar,C1-C9直链或支链烷基,和C2-C9直链或支链链烯基或炔基;和当Y为N时,R1和R2独立地选自Ar,氢,C1-C9直链或支链烷基,C2-C9直链或支链链烯基或炔基,C3-C7环烷基、环烯基或环炔基,C6-C14双环烷基、双环烯基或双环炔基,和C9-C21三环烷基、三环烯基或三环炔基;或R1和R2一起形成选自吡咯烷、咪唑烷、吡唑烷、哌啶和哌嗪的杂环5-6元环;Ar为碳环或杂环芳族部分,其未被取代或被一个或多个取代基取代;q为0-2;和n为0或1;和(ⅱ)可药用载体。
24.根据权利要求23的药物组合物,其中神经元活动选自对受损神经元的刺激、神经元再生的促进、神经变性的预防和神经疾病的治疗。
25.根据权利要求24的药物组合物,其中神经疾病选自由物理损伤或疾病状态引起的外周神经病、脑的物理损伤、脊髓的物理损伤、与脑损伤有关的中风和与神经变性有关的神经疾病。
26.根据权利要求25的药物组合物,其中与神经变性有关的神经疾病选自阿尔茨海默氏病、帕金森氏病和肌萎缩性侧索硬化。
27.根据权利要求23的药物组合物,其中J和K一起形成5-7元环。
28.根据权利要求23的药物组合物,其中Ar选自苯基,1-萘基,2-萘基,茚基,甘菊环基,芴基和蒽基;或选自如下的杂环:2-呋喃基,3-呋喃基,2-噻吩基,3-噻吩基,2-吡啶基,3-吡啶基,4-吡啶基,吡咯基,噁唑基,噻唑基,咪唑基,吡唑基,2-吡唑啉基,吡唑烷基,异噁唑基,异三唑基,1,2,3-噁二唑基,1,2,3-三唑基,1,3,4-噻二唑基,哒嗪基,嘧啶基,吡嗪基,1,3,5-三嗪基,1,3,5-三噻烷基,中氮茚基,吲哚基,异氮杂茚基,3H-吲哚基,二氢吲哚基,苯并[b]呋喃基,苯并[b]噻吩基,1H-吲唑基,苯并咪唑基,苯并噻唑基,嘌呤基,4H-喹嗪基,喹啉基,1,2,3,4-四氢喹啉基,异喹啉基,1,2,3,4-四氢异喹啉基,肉啉基,2,3-二氮杂萘基,喹唑啉基,喹喔啉基,1,8-二氮杂萘基,蝶啶基,咔唑基,吖啶基,吩嗪基,吩噻嗪基和吩噁嗪基;其中Ar是未取代的或被一个或多个取代基取代,所述取代基独立地选自卤素、羟基、硝基、-SO3H、三氟甲基、三氟甲氧基、C1-C9直链或支链烷基、C2-C9直链或支链链烯基、O-(C1-C9直链或支链烷基)、O-(C2-C9直链或支链链烯基)、O-苄基、O-苯基、1,2-亚甲二氧基、-NR4R5、羧基、N-(C1-C9直链或支链烷基或C2-C9直链或支链链烯基)羧酰胺、N,N-二-(C1-C9直链或支链烷基或C2-C9直链或支链链烯基)羧酰胺、吗啉基、哌啶基、O-X、CH2-(CH2)q-X、O-(CH2)q-X、(CH2)q-O-X和CH=CH-X;R4和R5独立地选自C1-C9直链或支链烷基,C2-C9直链或支链链烯基,氢和苄基;或R4和R5一起形成5-6元杂环;和X选自4-甲氧基苯基,2-吡啶基,3-吡啶基,4-吡啶基,吡唑基,喹啉基,3,5-二甲基异噁唑基,异噁唑基,2-甲基噻唑基,噻唑基,2-噻吩基,3-噻吩基和嘧啶基。
29.根据权利要求23的药物组合物,其中所述B和D中至少一个独立地由式-(CH2)r-(X’)-(CH2)s-Ar所代表,其中r为1-4;s为0-1;和各X’独立地选自CH2、O、S、SO、SO2和NR3,其中R3选自氢、C1-C9直链或支链烷基、C2-C9直链或支链链烯基或炔基和其中在氮原子和Ar之间形成桥的C1-C9桥接烷基。
30.根据权利要求23的药物组合物,其中Ar选自苯基,2-吡啶基,3-吡啶基,4-吡啶基,吲哚基,异氮杂茚基,喹啉基,异喹啉基,1,2,3,4-四氢异喹啉基和1,2,3,4-四氢喹啉基,其中所述Ar为未取代的或被一个或多个取代基取代,所述取代基独立地选自氢、羟基、硝基、三氟甲基、C1-C9直链或支链烷基、O-(C1-C9直链或支链烷基)、卤素、SO3H和NR3R4;和R3和R4独立地选自C1-C9直链或支链烷基,C2-C9直链或支链链烯基,氢和苄基;或R3和R4一起形成5-7元杂环。
31.根据权利要求23的药物组合物,其中Y为N,和R1和R2独立地选自氢、C3-C7环烷基、C6-C14双环烷基和C9-C21三环烷基。
32.根据权利要求31的药物组合物,其中该化合物为(2S)-1-[(2-甲基丁基)-氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
33.根据权利要求31的药物组合物,其中该化合物为(2S)-1-[(1’,1’-二甲基丙基)-氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
34.根据权利要求31的药物组合物,其中该化合物为(2S)-1-[(环己基)硫代氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
35.根据权利要求31的药物组合物,其中该化合物为(2S)-1-[(环己基)氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
36.根据权利要求31的药物组合物,其中该化合物为(2S)-1-[(1-金刚烷基)-硫代氨基甲酰基]吡咯烷-2-羧酸3-(3-吡啶基)-1-丙基酯。
38.根据权利要求37的药物组合物,其中神经元活动选自对受损神经元的刺激、神经元再生的促进、神经变性的预防和神经疾病的治疗。
39.根据权利要求38的药物组合物,其中神经疾病选自由物理损伤或疾病状态引起的外周神经病、脑的物理损伤、脊髓的物理损伤、与脑损伤有关的中风和与神经变性有关的神经疾病。
40.根据权利要求39的药物组合物,其中与神经变性有关的神经疾病选自阿尔茨海默氏病、帕金森氏病和肌萎缩性侧索硬化。
42.根据权利要求41的药物组合物,其中神经元活动选自对受损神经元的刺激、神经元再生的促进、神经变性的预防和神经疾病的治疗。
43.根据权利要求42的药物组合物,其中神经疾病选自由物理损伤或疾病状态引起的外周神经病、脑的物理损伤、脊髓的物理损伤、与脑损伤有关的中风和与神经变性有关的神经疾病。
44.根据权利要求43的药物组合物,其中与神经变性有关的神经疾病选自阿尔茨海默氏病、帕金森氏病和肌萎缩性侧索硬化。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/139,672 | 1998-08-25 | ||
US09/139,672 US6242468B1 (en) | 1997-02-27 | 1998-08-25 | Carbamate and urea compositions and neurotrophic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1313767A true CN1313767A (zh) | 2001-09-19 |
Family
ID=22487769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99810011A Pending CN1313767A (zh) | 1998-08-25 | 1999-08-24 | 氨基甲酸酯和脲组合物以及神经营养用途 |
Country Status (18)
Country | Link |
---|---|
US (1) | US6242468B1 (zh) |
EP (1) | EP1107757A2 (zh) |
JP (1) | JP2002523367A (zh) |
KR (1) | KR20010072992A (zh) |
CN (1) | CN1313767A (zh) |
AU (1) | AU5687999A (zh) |
BG (1) | BG105340A (zh) |
BR (1) | BR9912988A (zh) |
CA (1) | CA2341530A1 (zh) |
CZ (1) | CZ2001274A3 (zh) |
EA (1) | EA200100271A1 (zh) |
HU (1) | HUP0103166A3 (zh) |
IL (1) | IL140958A0 (zh) |
MX (1) | MXPA01001937A (zh) |
NO (1) | NO20010946L (zh) |
PL (1) | PL346759A1 (zh) |
SK (1) | SK2562001A3 (zh) |
WO (1) | WO2000010553A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104870421A (zh) * | 2011-12-27 | 2015-08-26 | 比皮艾思药物研发有限公司 | 用于预防或治疗als的苯基氨基甲酸酯化合物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7008960B1 (en) | 1999-03-02 | 2006-03-07 | Vitreo-Retinal Technologies, Inc. | Agents for intravitreal administration to treat or prevent disorders of the eye |
WO2001002363A2 (en) * | 1999-07-06 | 2001-01-11 | Vertex Pharmaceuticals Incorporated | N-substituted glycine derivatives |
US7977385B2 (en) * | 2000-03-02 | 2011-07-12 | Numoda Biotechnologies, Inc. | Agents for corneal or intrastromal administration to treat or prevent disorders of the eye |
US20030199574A1 (en) | 2000-03-02 | 2003-10-23 | Vitreo-Retinal Technologies, Inc. | Treatment of ophthalmic disorders using urea and urea derivatives |
US20050137124A1 (en) * | 2002-08-09 | 2005-06-23 | Vitreo-Retinal Technologies, Inc. A California Corporation | Agents for intravitreal administration to treat or prevent disorders of the eye |
EP1402888A1 (en) * | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
GT200500035A (es) | 2004-03-02 | 2005-10-24 | Macrolidos y metodos para producir los mismos | |
CN1929837A (zh) * | 2004-03-02 | 2007-03-14 | 惠氏公司 | 作为神经保护剂和/或神经再生剂的非免疫抑制的亲免素配体 |
WO2007061554A2 (en) * | 2005-10-21 | 2007-05-31 | Purdue Research Foundation | Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5214034A (en) | 1986-09-26 | 1993-05-25 | Mitsui Toatsu Chemicals, Incorporated | Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same |
FI874163A (fi) | 1986-09-26 | 1988-03-27 | Mitsui Toatsu Chemicals | Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet. |
IT1206078B (it) | 1987-06-03 | 1989-04-14 | Polifarma Spa | Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico |
US5232923A (en) | 1988-03-18 | 1993-08-03 | Mitsui Toatsu Chemicals, Incorporated | Catechol derivatives and pharmaceutical preparations containing same |
US5166317A (en) | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
US5215969A (en) | 1989-08-11 | 1993-06-01 | Hahnemann University | Dopaminergic neurotrophic factor for treatment of Parkinson's disease |
US5620971A (en) | 1991-05-09 | 1997-04-15 | Vertex Pharmaceuticals Incorporated | Biologically active acylated amino acid derivatives |
US5744485A (en) | 1994-03-25 | 1998-04-28 | Vertex Pharmaceuticals Incorporated | Carbamates and ureas as modifiers of multi-drug resistance |
IL115685A (en) * | 1994-11-16 | 2000-08-31 | Vertex Pharma | Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof |
US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
US5717092A (en) | 1996-03-29 | 1998-02-10 | Vertex Pharmaceuticals Inc. | Compounds with improved multi-drug resistance activity |
US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
US5780484A (en) | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
US5811434A (en) | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
US5935989A (en) * | 1996-12-31 | 1999-08-10 | Gpi Nil Holdings Inc. | N-linked ureas and carbamates of heterocyclic thioesters |
ZA98825B (en) * | 1997-02-27 | 1998-10-19 | Guilford Pharm Inc | Method of using neurotrophic carbamates and ureas |
-
1998
- 1998-08-25 US US09/139,672 patent/US6242468B1/en not_active Expired - Fee Related
-
1999
- 1999-08-24 EP EP99943869A patent/EP1107757A2/en not_active Withdrawn
- 1999-08-24 CN CN99810011A patent/CN1313767A/zh active Pending
- 1999-08-24 AU AU56879/99A patent/AU5687999A/en not_active Abandoned
- 1999-08-24 BR BR9912988-4A patent/BR9912988A/pt not_active IP Right Cessation
- 1999-08-24 KR KR1020017002444A patent/KR20010072992A/ko not_active Application Discontinuation
- 1999-08-24 JP JP2000565875A patent/JP2002523367A/ja active Pending
- 1999-08-24 SK SK256-2001A patent/SK2562001A3/sk unknown
- 1999-08-24 PL PL99346759A patent/PL346759A1/xx unknown
- 1999-08-24 HU HU0103166A patent/HUP0103166A3/hu unknown
- 1999-08-24 CZ CZ2001274A patent/CZ2001274A3/cs unknown
- 1999-08-24 CA CA002341530A patent/CA2341530A1/en not_active Abandoned
- 1999-08-24 WO PCT/US1999/019261 patent/WO2000010553A2/en not_active Application Discontinuation
- 1999-08-24 IL IL14095899A patent/IL140958A0/xx unknown
- 1999-08-24 EA EA200100271A patent/EA200100271A1/ru unknown
- 1999-08-24 MX MXPA01001937A patent/MXPA01001937A/es not_active IP Right Cessation
-
2001
- 2001-02-23 NO NO20010946A patent/NO20010946L/no not_active Application Discontinuation
- 2001-03-14 BG BG105340A patent/BG105340A/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104870421A (zh) * | 2011-12-27 | 2015-08-26 | 比皮艾思药物研发有限公司 | 用于预防或治疗als的苯基氨基甲酸酯化合物 |
Also Published As
Publication number | Publication date |
---|---|
AU5687999A (en) | 2000-03-14 |
IL140958A0 (en) | 2002-02-10 |
WO2000010553A2 (en) | 2000-03-02 |
JP2002523367A (ja) | 2002-07-30 |
HUP0103166A3 (en) | 2002-10-28 |
EP1107757A2 (en) | 2001-06-20 |
KR20010072992A (ko) | 2001-07-31 |
CA2341530A1 (en) | 2000-03-02 |
WO2000010553A3 (en) | 2000-05-18 |
MXPA01001937A (es) | 2002-04-24 |
BG105340A (en) | 2001-12-29 |
CZ2001274A3 (cs) | 2001-09-12 |
US6242468B1 (en) | 2001-06-05 |
SK2562001A3 (en) | 2001-09-11 |
NO20010946D0 (no) | 2001-02-23 |
PL346759A1 (en) | 2002-02-25 |
HUP0103166A2 (hu) | 2002-05-29 |
BR9912988A (pt) | 2001-10-02 |
NO20010946L (no) | 2001-02-23 |
EA200100271A1 (ru) | 2001-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1123360C (zh) | 亲环素旋转异构酶活性抑制剂 | |
US6245783B1 (en) | Method of using neurotrophic sulfonamide compounds | |
EP0934287B1 (en) | Heterocyclic esters and amides | |
JP3561843B2 (ja) | ロタマーゼ酵素活性の小分子阻害剤 | |
CN1249681A (zh) | 杂环酯,酰胺,硫代酸酯和酮的n-氧化物 | |
KR19990067257A (ko) | 로타마아제효소활성억제제 | |
SK26599A3 (en) | Heterocyclic thioesters and ketones | |
US6184243B1 (en) | N-linked ureas and carbamates of heterocyclic thioesters | |
CN1313767A (zh) | 氨基甲酸酯和脲组合物以及神经营养用途 | |
JP2001513772A (ja) | 神経栄養性カルバミン酸エステル類及び尿素類の使用方法 | |
CN1717390A (zh) | 用于治疗神经病的哌嗪和哌啶衍生物 | |
JP2002515050A (ja) | ヘテロ環式チオエステルのn−結合尿素およびカルバメート | |
CN1529599A (zh) | 可用于治疗神经元损伤的无环哌嗪和哌啶衍生物 | |
US20020013344A1 (en) | Rotamas enzyme activity inhibitors | |
CN1323294A (zh) | 环状酯或酰胺衍生物 | |
CN1205635A (zh) | 旋转异构酶活性抑制剂 | |
MXPA99002814A (en) | Heterocyclic esters and amides | |
MXPA98003356A (en) | Inhibitors of the activity of enzima rotam | |
MXPA99007938A (en) | Method of using neurotrophic carbamates and ureas | |
MXPA99007384A (en) | Method of using neutrophic sulfonamide compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |